MedTrace Logo

Efficacy and Safety of Neosil on Chronic Effluvium

NCT03659201 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 232

Last updated 2020-04-07

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy of Neosil in the treatment of chronic effluvium

Conditions

  • Chronic Telogen Effluvium

Interventions

DRUG

Neosil complete

Oral, during 24 weeks.

DRUG

Pantogar

Oral, placebo for 12 weeks and pantogar for 12 weeks.

DRUG

Neosil

Oral, during only 12 weeks.

Sponsors & Collaborators

  • Luxbiotech

    collaborator UNKNOWN

  • EMS

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-03
Primary Completion
2019-06-04
Completion
2020-03-30

Countries

  • Brazil

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03659201 on ClinicalTrials.gov